oxazolidin-2-one has been researched along with cadazolid in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (93.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Baldoni, D; Dingemanse, J; Gutierrez, M; Timmer, W | 1 |
| Athanasiou, A; Baines, SD; Chilton, CH; Crowther, GS; Freeman, J; Locher, HH; Todhunter, SL; Wilcox, MH | 1 |
| Chen, X; Enderlin, M; Fournier, E; Hubschwerlen, C; Keck, W; Kelly, CP; Klenk, A; Locher, HH; Pfaff, P; Ritz, D; Schroeder, S; Seiler, P | 1 |
| Buitrago, M; Charef, P; Cornely, OA; Gerding, DN; Kracker, H; Louie, T; Nord, CE; Talbot, GH; Wilcox, M | 1 |
| Desnica, B; Dingemanse, J; Gehin, M | 1 |
| Best, E; Buitrago, M; Charef, P; Cornely, OA; Gerding, DN; Hecht, DW; Kracker, H; Locher, HH; Louie, T; Nord, CE; Osmolski, JR; Sambol, S; Talbot, GH; Wilcox, M | 1 |
| Clozel, M; Enderlin-Paput, M; Locher, HH; Pfaff, P; Ritz, D; Seiler, P; Weiss, M | 1 |
| Parkes, AL; Yule, IA | 1 |
| Martin, J; Wilcox, M | 1 |
| Alam, MJ; Bassères, E; Dotson, KM; Endres, BT; Garey, KW | 1 |
| Alam, MJ; Bassères, E; Endres, BT; Garey, KW | 1 |
| Birchall, S; Corbett, D; Locher, HH; Skinner, K; Thommes, P | 1 |
| Guery, B | 1 |
| Buitrago, M; Cornely, OA; Gerding, DN; Gheorghe Diaconescu, I; Grill, S; Kracker, H; Louie, TJ; Marrast, AC; Murta de Oliveira, C; Nord, CE; Preotescu, L; Pullman, J; Talbot, GH; Wilcox, MH | 1 |
| Boehringer, D; Bur, D; Caspers, P; Leibundgut, M; Locher, HH; Ritz, D; Rueedi, G; Scaiola, A | 1 |
| Albert, E; Ali, N; Muhammad, A; Rawish, F; Sabih, R; Simcha, W | 1 |
5 review(s) available for oxazolidin-2-one and cadazolid
| Article | Year |
|---|---|
Hybrid antibiotics - clinical progress and novel designs.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Drug Design; Drug Resistance, Multiple, Bacterial; Humans; Oxazolidinones | 2016 |
New and emerging therapies for Clostridium difficile infection.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Neutralizing; Benzimidazoles; Broadly Neutralizing Antibodies; Clostridioides difficile; Clostridium Infections; Fecal Microbiota Transplantation; Humans; Lipopeptides; Oxazolidinones; Peptides, Cyclic; Pyridines; Recurrence; Secondary Prevention | 2016 |
Novel antibiotics in development to treat Clostridium difficile infection.
Topics: Anti-Bacterial Agents; Benzimidazoles; Benzopyrans; Clinical Trials as Topic; Clostridium Infections; Depsipeptides; Humans; Lipopeptides; Oxazolidinones; Peptides, Cyclic; Pyridines; Thiazoles; Thiophenes | 2017 |
Cadazolid for the treatment of Clostridium difficile.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Lipopeptides; Oxazolidinones; Peptides, Cyclic; Treatment Outcome | 2017 |
Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis.
Topics: Animals; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Humans; Oxazolidinones; Randomized Controlled Trials as Topic; Vancomycin | 2020 |
3 trial(s) available for oxazolidin-2-one and cadazolid
| Article | Year |
|---|---|
Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Diarrhea; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Oxazolidinones; Patient Safety; Recurrence; Vancomycin | 2015 |
Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Drug-Related Side Effects and Adverse Reactions; Feces; Female; Humans; Male; Middle Aged; Oxazolidinones; Plasma; Time Factors; Young Adult | 2015 |
Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Double-Blind Method; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Oxazolidinones; Ribotyping; Vancomycin; Young Adult | 2016 |
8 other study(ies) available for oxazolidin-2-one and cadazolid
| Article | Year |
|---|---|
Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Blood Chemical Analysis; Clostridioides difficile; Diarrhea; Feces; Healthy Volunteers; Humans; Male; Middle Aged; Oxazolidinones; Placebos; Urine | 2014 |
In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection.
Topics: Bacterial Load; Clostridioides difficile; Clostridium Infections; Gastrointestinal Tract; Humans; Microbial Sensitivity Tests; Microbial Viability; Models, Theoretical; Oxazolidinones; Treatment Outcome | 2014 |
In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Clostridioides difficile; Clostridium Infections; Cricetinae; Enterocolitis, Pseudomembranous; Enterotoxins; Female; Fluoroquinolones; Humans; Linezolid; Male; Metronidazole; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Oxazolidinones; Spores, Bacterial; Survival Analysis; Vancomycin | 2014 |
Cadazolid Does Not Promote Intestinal Colonization of Vancomycin-Resistant Enterococci in Mice.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Clostridioides difficile; Colony Count, Microbial; Diarrhea; Enterocolitis, Pseudomembranous; Fidaxomicin; Intestines; Metronidazole; Mice; Microbial Sensitivity Tests; Oxazolidinones; Streptococcal Infections; Treatment Outcome; Vancomycin; Vancomycin Resistance; Vancomycin-Resistant Enterococci | 2016 |
Time-kill kinetics of cadazolid and comparator antibacterial agents against different ribotypes of Clostridium difficile.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Kinetics; Microbial Sensitivity Tests; Oxazolidinones; Ribotyping; Vancomycin | 2018 |
Clostridium difficile infection trials: what is the primary endpoint?
Topics: Clostridioides difficile; Clostridium Infections; Double-Blind Method; Enterocolitis, Pseudomembranous; Humans; Oxazolidinones | 2019 |
Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Clinical Trials, Phase III as Topic; Clostridioides difficile; Clostridium Infections; Diarrhea; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Oxazolidinones; Placebos; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2019 |
Structural basis of translation inhibition by cadazolid, a novel quinoxolidinone antibiotic.
Topics: Acetamides; Anti-Bacterial Agents; Clostridium Infections; Cryoelectron Microscopy; Escherichia coli; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Oxazolidinones; Peptidyl Transferases; Protein Synthesis Inhibitors; Ribosomes; RNA, Transfer, Met; Staphylococcus aureus | 2019 |